Details for Patent: 10,337,003

Which drugs does patent 10,337,003 protect, and when does it expire?

Patent 10,337,003 protects EXONDYS 51 and is included in one NDA.

This patent has twenty-three patent family members in thirteen countries.

Summary for Patent: 10,337,003

Title:	Compositions for treating muscular dystrophy
Abstract:	Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Inventor(s):	Kaye; Edward M. (Cambridge, MA)
Assignee:	Sarepta Therapeutics, Inc. (Cambridge, MA)
Application Number:	15/359,152
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,337,003

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes						TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes						TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

International Family Members for US Patent 10,337,003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014233456
Australia	2019203505
Australia	2020260492
Brazil	112015022998